New Haven-born Alexion Pharmaceuticals, whose blockbuster blood-disorder drug Soliris made it one of the Elm City’s biggest biotech success stories a decade ago, is now officially the rare disease arm of pharma giant AstraZeneca.
First announced last December, the acquisition has been billed by industry observers as the biggest pharma deal of 2020.